Morepen Labs Makes First US ANDA Submission
Morepen strengthens its CDMO capabilities with its first US ANDA submission, expanding formulation, bioequivalence and regulatory expertise for regulated markets.
Morepen CDMO Capabilities | 30/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy